Blood transfusion, colloid therapy and the possible saving of albumin volumes during surgery: data analysis of the survey for certified hospitals of the Japanese Society of Anesthesiologists

• Published in: Journal of anesthesia 2016-06, Vol.30 (3), p.384-390
• Main Author: Miyao, Hideki
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Albumin; Anesthesiology; Anesthesiology - statistics & numerical data; Blood Loss, Surgical; Blood Transfusion - statistics & numerical data; Blood Transfusion, Autologous - statistics & numerical data; Child; Child, Preschool; Colloids - therapeutic use; Critical Care Medicine; Emergency Medicine; Female; Fluid therapy; General Surgery - statistics & numerical data; Health Care Surveys; Hospitals - statistics & numerical data; Humans; Hydroxyethyl Starch Derivatives - therapeutic use; Infant; Infant, Newborn; Intensive; Japan; Male; Measurement; Medicine; Medicine & Public Health; Middle Aged; Original; Original Article; Pain Medicine; Physiological aspects; Plasma Substitutes - therapeutic use; Serum Albumin; Surveys; Young Adult
• ISSN: 0913-8668; 1438-8359
• DOI: 10.1007/s00540-015-2136-3

Purpose Third-generation hydroxyethyl starch (HES) 130/0.4 has a larger dose limitation (up to 50 mL/kg/day) than HES 70/0.5 (up to 1000 mL/day) which has been used in Japan for 40 years. The aim of this study was to survey the current intraoperative blood transfusion and volume therapy and to predict the possible reduction of intraoperative albumin consumption assuming further replacement by HES 130/0.4 using data obtained from a survey by the Japanese Society of Anesthesiologists (JSA), although HES130/0.4 was not launched in Japan during this survey period. Methods In a JSA survey conducted at JSA-certified hospitals, 12,856 patients with a certain amount of blood loss were analyzed for 1 month (April, 2012). The patients were divided into two groups—group A included patients aged ≥11 years and group B included patients aged